Hypersensitivity Pneumonitis vs. Drug-Induced Lung Injury: Understanding Cough and Breathlessness

You take a new prescription, and within days, you start gasping for air. A dry, hacking cough won't go away, and simple tasks like climbing stairs leave you exhausted. It feels like your lungs are fighting you. You might assume the medicine is causing an allergic reaction, but the reality is often more complex. While true hypersensitivity pneumonitis is rarely caused by pills or injections, medications can trigger a very similar-and equally dangerous-condition known as drug-induced interstitial lung disease.

Understanding the difference between these two conditions is critical. One requires you to change your environment; the other requires you to change your medication. Misdiagnosing either can lead to permanent scarring of the lungs. Let’s break down what is actually happening inside your chest, how doctors tell them apart, and what steps you need to take if you suspect your health is declining due to exposure or treatment.

What Is Hypersensitivity Pneumonitis?

Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis, is an immune-mediated lung disease. It occurs when your body overreacts to inhaling specific antigens-tiny particles from organic or inorganic sources. Unlike asthma, which affects the larger airways, HP targets the alveoli, the tiny air sacs where oxygen exchange happens.

The mechanism is straightforward but damaging. When you breathe in a triggering antigen, your immune system launches an inflammatory attack on the lung tissue. This causes swelling and the formation of poorly formed granulomas (clusters of immune cells). If the exposure stops, this inflammation often resolves. However, repeated exposure leads to chronic inflammation, fibrosis (scarring), and eventually irreversible lung damage.

Historically, this condition was linked to occupational hazards. Think of "farmer's lung" caused by moldy hay, or "bird fancier's lung" triggered by proteins in bird feathers and droppings. More recently, domestic sources like contaminated humidifiers, hot tubs, and air conditioning units have become common culprits. The key takeaway here is that classic HP is almost exclusively an inhalational disorder, not a systemic one.

Can Medications Cause Hypersensitivity Pneumonitis?

This is where confusion sets in. Patients often hear "pneumonitis" and assume any cause fits. However, medical consensus, including guidelines from the Merck Manual and the National Organization for Rare Disorders, states that true hypersensitivity pneumonitis is exceptionally rare when caused by medications. Why? Because HP requires direct inhalation of an antigen to trigger the localized alveolar inflammation characteristic of the disease.

When you swallow a pill or receive an injection, the drug enters your bloodstream. It does not typically sit in the alveoli waiting to be inhaled. Therefore, while medications can certainly hurt your lungs, they usually do so through a different pathway called Drug-Induced Interstitial Lung Disease (DILD).

DILD mimics many symptoms of HP, such as cough and breathlessness, but the underlying pathology is different. Instead of the granulomas seen in HP, DILD often presents with patterns like organizing pneumonia, eosinophilic pneumonia, or diffuse alveolar damage. Recognizing this distinction is vital because the treatment protocol changes completely.

Medications That Trigger Lung Injury

Even though they don’t cause classic HP, certain drugs are notorious for causing severe lung inflammation that looks and feels just like it. If you are taking any of the following, you need to be vigilant about respiratory symptoms:

• Amiodarone: An antiarrhythmic drug used for heart rhythm issues. It can cause phospholipidosis, leading to pulmonary toxicity in up to 10-15% of patients on long-term therapy.
• Nitrofurantoin: Commonly prescribed for urinary tract infections. It can trigger acute interstitial pneumonitis, sometimes even after years of safe use.
• Bleomycin: A chemotherapy agent known for direct cytotoxic injury to lung tissue, causing fibrosis.
• Methotrexate: Used for autoimmune diseases and cancer, it can induce hypersensitivity-like reactions in the lungs, though true granulomatous HP is rare.
• Certain Antibiotics: Sulfonamides and penicillins have been linked to eosinophilic pneumonia, a type of DILD.

The onset varies wildly. Some reactions happen within hours (acute), others develop over weeks (subacute), and some creep in silently over months (chronic). This variability makes self-diagnosis nearly impossible without medical testing.

Symptoms: Cough and Breathlessness Explained

Whether the cause is environmental HP or drug-induced DILD, the symptom profile is strikingly similar. This overlap is why imaging and biopsy are so crucial.

In acute cases, symptoms strike 4 to 8 hours after exposure. You may experience fever, chills, muscle aches, and a sudden onset of shortness of breath. The cough is typically dry and non-productive. If the trigger is removed (e.g., leaving a moldy basement or stopping a drug), symptoms often resolve within 24 to 48 hours.

Subacute cases present with progressive fatigue, weight loss, and a persistent cough that lasts for weeks. Breathlessness worsens gradually, making daily activities difficult. Patients often feel generally unwell, describing a sense of heaviness in the chest.

Chronic cases are the most dangerous because they are insidious. Symptoms develop slowly over months or years. You might notice that you get winded walking up one flight of stairs when you didn’t before. Clubbing of the fingers (where the tips enlarge) can occur in advanced stages. At this point, significant fibrosis may already be present, meaning the lung tissue has permanently scarred.

How Doctors Diagnose the Cause

Diagnosing lung inflammation isn’t about finding a single "yes/no" test. It’s a puzzle that requires piecing together history, imaging, and lab results. Here is how clinicians differentiate between environmental HP and medication-induced injury:

A High-Resolution Computed Tomography (HRCT) scan is often the first major clue. In acute HP, radiologists look for centrilobular ground-glass opacities and mosaic attenuation (patchy areas of dark and light lung tissue indicating air trapping). In contrast, drug-induced injuries might show diffuse consolidation or a different pattern of fibrosis.

If imaging is inconclusive, a bronchoscopy with bronchoalveolar lavage (BAL) may be performed. BAL fluid analysis in HP typically shows a high percentage of lymphocytes. In some drug reactions, particularly those involving antibiotics or anticonvulsants, you might see elevated eosinophils instead.

Treatment and Management Strategies

The cornerstone of treatment for both conditions is removal of the offending agent. For environmental HP, this means strict avoidance of the antigen. This could involve removing pets, cleaning HVAC systems, wearing respirators at work, or even relocating if the home environment is heavily contaminated.

For drug-induced lung injury, the medication must be stopped immediately under medical supervision. Switching to an alternative therapy is necessary to manage the underlying condition (such as infection or arrhythmia) without further lung damage.

Inflammatory phases of both conditions are often treated with glucocorticoids, such as prednisone. A typical regimen might start at 0.5 mg/kg/day and taper over 6 to 12 weeks. These steroids reduce inflammation quickly, providing relief from breathlessness and cough. However, they do not reverse existing fibrosis.

If chronic fibrosis has developed, antifibrotic therapies like nintedanib may be considered. Recent trials, such as the INJOURNEY study, have shown that these drugs can slow the decline of lung function in progressive fibrotic lung diseases. Pulmonary rehabilitation and supplemental oxygen are also critical supportive measures for patients with reduced lung capacity.

Prognosis and Long-Term Outlook

The outcome depends heavily on timing. In acute cases where the trigger is identified and removed early, recovery is often complete. Up to 70-80% of acute HP cases resolve fully without permanent damage.

Chronic cases are more challenging. Once honeycombing (advanced scarring) appears on HRCT scans, the damage is largely irreversible. The 5-year survival rate for chronic HP ranges from 50% to 80%, depending on the extent of fibrosis and whether the antigen exposure continues. Factors predicting poorer outcomes include a significant drop in forced vital capacity (FVC) and diffusion capacity (DLCO) over six months.

Interestingly, active cigarette smoking appears to decrease the risk of developing hypersensitivity pneumonitis, possibly due to altered mucociliary clearance or immune modulation. However, smoking accelerates the progression of fibrosis once lung disease is established, making cessation crucial for all patients with interstitial lung disease.